Association of MnSOD AA Genotype with the Progression of Prostate Cancer.
Association of MnSOD AA Genotype with the Progression of Prostate Cancer.
复制标题
DOI：
10.1371/journal.pone.0131325
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Haas GP
中科院分区：
文献类型：
--
作者：
Iguchi T;Wang CY;Delongchamps NB;Kato M;Tamada S;Yamasaki T;de la Roza G;Nakatani T;Haas GP
探讨锰超氧化物歧化酶（MnSOD）基因多态性是否与前列腺癌的临床意义相关。前列腺取自 194 名 45 岁或以上、没有前列腺癌病史的已故男性。对前列腺进行连续切片和组织学检查。采用聚合酶链式反应限制性片段长度多态性分析测定标本的MnSOD基因型。在这 194 名男性中，分别有 31 人和 26 人患有临床上不显着的前列腺癌和显着的前列腺癌。在 70 岁以下和 70 岁以上的男性中，有临床意义的癌症分别占 29% 和 58%。随着年龄的增长，显着癌症的年龄特定比例显着增加（p<0.001）。与其他基因型（VA 和 VV 一起）相比，MnSOD AA 与所有年龄段的显着前列腺癌相关，比值比 (OR) 2.34，95% 置信区间 (CI) 0.99-5.49，在 69 岁以上男性中（OR 4.89，95% CI 1.51-15.8），但与 70 岁以下男性无关。无论年龄如何，该基因型与临床上不显着的癌症无关。显着性癌症和非显着性癌症之间的比较，69 岁以上男性中 MnSOD AA 的 OR (95% CI) 为 5.04 (1.05-24.2)（敏感性 0.57，特异性 0.78，阳性预测值 0.78）。 MnSOD 多态性与 69 岁以上男性前列腺癌的临床意义密切相关，但与 70 岁以下男性无关，表明氧化应激可能与疾病的进展有关。 MnSOD 可能是预测前列腺癌进展潜力的临床有用标志物。
To investigate whether manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with the clinical significance of prostate cancer. Prostates were obtained from 194 deceased men 45 years or older who did not have a history of prostate cancer. Serial sections and histological examinations of the prostate were performed. The MnSOD genotypes of the specimens were determined by polymerase chain reaction restriction fragment length polymorphism analysis. Of the 194 men, 31 and 26 had clinically insignificant and significant prostate cancer. Clinically significant cancer comprised 29% and 58% of the cancers in men <70 and >70 years old, respectively. The age-specific proportion of significant cancer significantly increased with the advance of age (p<0.001). MnSOD AA, as compared with the other genotypes (VA and VV together), was associated with significant prostate cancer across all ages, odds ratio (OR) 2.34, 95% confidence interval (CI) 0.99-5.49, and in men older than 69 years (OR 4.89, 95% CI 1.51-15.8), but not in men younger than 70 years. The genotype was not associated with clinically insignificant cancer regardless of age. The comparison between significant and insignificant cancer, the OR (95% CI) for MnSOD AA was 5.04 (1.05-24.2) (sensitivity 0.57, specificity 0.78, positive predictive value 0.78) in men older than 69 years. MnSOD polymorphism is strongly associated with the clinical significance of prostate cancer in men older than 69 years, but not in men younger than 70 years suggesting that oxidative stress may be involved in the progression of the disease. MnSOD may be a clinically useful marker to predict the potential of progression of prostate cancer.
登录
查看更多内容
影响因子：
254.7
作者：
Siegel, Rebecca;Ma, Jiemin;Jemal, Ahmedin
通讯作者：
Jemal, Ahmedin
DOI：
10.1007/s00432-009-0742-x
发表时间：
2010-07-01
影响因子：
3.6
作者：
Mao, Chen;Qiu, Li-Xin;Chen, Qing
通讯作者：
Chen, Qing
DOI：
10.1097/00008571-200303000-00004
发表时间：
2003-03-01
期刊：
PHARMACOGENETICS
影响因子：
--
作者：
Sutton, A;Khoury, H;Degoul, F
通讯作者：
Degoul, F
DOI：
10.1093/jnci/93.23.1818
发表时间：
2001-12-05
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Wang, LI;Miller, DP;Christiani, DC
通讯作者：
Christiani, DC
影响因子：
120.7
作者：
EPSTEIN, JI;WALSH, PC;BRENDLER, CB
通讯作者：
BRENDLER, CB